ERBB2 and neoplasm: In addition, evaluation of the endometrial cohort in the phase II TAPUR trial reported only a mild anti-tumor activity of combined trastuzumab and pertuzumab in heavily treated patients with HER2 amplifications, with an ORR of 7%, DCR of 37%, PFS of 16 weeks and OS of 61 weeks [82].